Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMIT-BC: Samuraciclib plus fulvestrant in HR-positive, HER2-negative metastatic breast cancer
2023-503903-27-00Phase 2Completed
- Sponsor
- Carrick Therapeutics
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of samuraciclib in breast cancer (2 arms), sponsored by Carrick Therapeutics. Primary endpoint: Clinical benefit response (CBR). Started Sep 2023; status: completed.
02
Drugs
samuraciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-503903-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503903-27-00.